Abstract
Despite many years of clinical experimentation with commercially available short-, intermediate-, and long-acting insulin preparations, good metabolic control is still difficult to attain in a large proportion of insulin-dependent diabetics. Two basic problems emerge from the clinical studies: 1. the rate of insulin uptake after sub-cutaneous injection of conventional short-acting preparations is too slow; and 2. the pharmacokinetics of intermediate- and long-acting preparations vary too much.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Bradbury AF, Ko AS, Massey DE, Salokangas A, Smyth DG, Sabery GA, Webb FW, Steward GA (1973) The quest for a latent action insulin. Postgrad Med J (Suppl) 49: 945–948
Brake AJ, Merryweather JP, Coit DG, Heberlein UA, Masiarz FR, Mullenbach GT, Urdea MS, Valenzuela P, Barr PJ (1984) B-factor-directed synthesis and secretion of mature foreign proteins in Saccharomyces cerevisiae. Proc Natl Acad Sci USA 81: 4642–4646
Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, Havelund S, Melberg SG, Norris F, Norris K, Snel L, Sørensen AR, Voigt HO (1988) Monomeric insulins obtained by protein engineering and their medical implications. Nature 333: 679–682
Fischer WH, Saunders D, Brandenburg D, Wollmer A, Zahn H (1985) A shortened insulin with full in vitro potency. Biol Chem Hoppe-Seyler 366: 521–525
Gattner HG (1975) Darstellung und Eigenschaften von Des-Pentapeptid (B26-30)-Rinderinsulin. Hoppe-Seylers Z Physiol Chem 356: 1397–1404
Grau U (1985) Insulin-Arg2: A new retard-principle based on a natural proinsulin-derived processing intermediate. Diabetes Res Clin Pract Suppl 1: S204
Krayenbühl C, Rosenberg T (1946) Cryastalline protamine-insulin. Reports Steno Mem Hosp Nordisk Insulinlab 1: 60–73
Kunkel TA (1985) Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci USA 82: 448–492
Markussen J, Hougaard P, Ribel U, Sørensen AR, Sørensen E (1987a) Soluble, prolonged-acting insulin derivatives. I. Degree of protaction and crystallizability of insulins substituted in the termini of the B-chain. Protein Eng 1: 205–213
Markussen J, Diers I, Englsgaard A, Hansen MT, Hougaard P, Langkjaer L, Norris K, Ribel U, Sørensen AR, Sørensen E, Voigt HO (1987b) Soluble, prolonged-acting insulin derivatives. II. Degree of protaction and crystallizability of insulins substituted in positions A17, B8, B13, B27. Protein Eng 1: 215–223
Sonne O (1985) In vitro biological characterization of iodinated insulin preparations. In: Larner O, Poll SL (eds) Methods in diabetes research, vol I: Laboratory Methods. Wiley, New York, pp 433–451
Zahn H, Naithani VK, Gattner HG, Biillesbach EE, Tharum PM (1981) Protein-Semisynthese mit Hilfe gemischter Anhydride und Enzyme. Naturwissenschaften 68: 56–62
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Hansen, F.B. et al. (1989). Insulin Analogues — Potentials for Improving Diabetes Treatment. In: Creutzfeldt, W., Lefèbvre, P.J. (eds) Diabetes Mellitus: Pathophysiology and Therapy. Bayer AG Centenary Symposium. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74255-2_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-74255-2_13
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-50506-8
Online ISBN: 978-3-642-74255-2
eBook Packages: Springer Book Archive